Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
More than three years interval between the first and second dose of Shingrix; This non-serious case was reported by a physician via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (Patient took first dose on unknown date). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: More than three years interval between the first and second dose of Shingrix). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 27-MAR-2025 The reporter told that if more than three years went by between the first and second dose of the vaccination did the patient needed to start the series over or just give the second dose now. The interval between first and second dose of the Shingrix was more than three years which led to drug dose administration interval too long. The reporter did not want to provided personal information but yes that what occurred. The second dose of Shingrix which it appeared correct based on CDC guidelines but wanted to double check. No worries if it was not a simple yes or no answer and chat dropped while attempting to obtain additional information.